Study of Shigella Vaccines in Man.
Annual rept. 16 Aug 73-15 Aug 74,
MARYLAND UNIV BALTIMORE DIV OF INFECTIOUS DISEASES
Pagination or Media Count:
Studies have continued to evaluate the safety, biologic properties and efficacy of various oral Shigella vaccine candidates. The most recent vaccine candidates employed have been Escherichia coli bearing Shigella group antigens. These vaccine candidates are noteworthy in that they are completely safe with no potential for reversion and they appear to proliferate within the human bowel. In several protocols, however, involving concomitant challenge of both vaccinated and non-vaccinated volunteers with varied doses of virulent S. flexneri 2a, attack rates were similar and a protective effect of the vaccine strain could not be demonstrated.
- Medicine and Medical Research